JPRN-UMIN000019412已完成未知
Pharmacokinetic study of gefitinib in patients with non-small cell lung cancer - Pharmacokinetic study of gefitinib in patients with non-small cell lung cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with interstitial pneumonitis identified by chest X-ray
研究者
相似试验
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
已完成
不适用
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.non-small cell lung cancerJPRN-UMIN000000637Juntendo University, School of Medicine20
未知
不适用
PhaseII stady of gefitinib and in patients with relapsed advanced non-small cell lung cancerJPRN-C000000142Department of Medical Oncology Kinki University School of Medicine30
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33
进行中（未招募）
1 期
Evaluation of efficacy of gefitinib drug in patients with non-small cell tumors with EGFR and TP53 gene mutatioon-small cell lung cancer (NSCLC) at the stageadvanced / metastatic with receptor sensitizing mutation for growth factorepidermal (EGFR)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002626-20-ITAZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA54